Rationale: It is often challenging to discriminate between intrahepatic cholangiocarcinoma (ICC) and metastatic liver tumors, especially when the hepatic tumor is small and of a mass-forming type.
Introduction
KRAS is a critical proto-oncogene involved in signal transduction, and plays a central role in cancer cell proliferation, invasion, and metastasis. [1] KRAS mutations are common in colorectal cancer, pancreatic ductal adenocarcinoma (PDAC), intrahepatic cholangiocarcinoma (ICC), and lung cancer. [2] [3] [4] [5] Recent advancements in DNA extraction and mutation testing techniques have enabled the identification of KRAS mutation status from formalin-fixed paraffin-embedded (FFPE) needle biopsy samples. [6] Herein, we report a case of synchronous pancreatic cancer and ICC diagnosed by KRAS mutational analysis of FFPE needle biopsy samples.
Case report
A 69-year-old woman presented at our hospital with a small solid tumor in the head of the pancreas that was previously discovered during a medical checkup. She was a nonsmoker and had been treated for hypertension for the past 5 years with Nifedipine (20 x0200A;mg daily). She reported no symptoms, including no abdominal pain. Her serum carbohydrate antigen 19 to 9 level was markedly elevated (833.2 U/mL). A contrast-enhanced computed tomography (CECT) scan revealed a poorly enhanced nodule (9 mm in size) in the head of the pancreas (Fig. 1A) . Additionally, a 14-mm nodule was also observed in the caudate lobe of the liver. The hepatic nodule exhibited low vascularity on CECT and was suspected of being either a pancreatic tumor metastasis or primary ICC (Fig. 1B) . No lymph node or distant metastasis was detected on CECT. On gadolinium ethoxybenzyl Editor: Andrea Ruzzenente.
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The authors have no conflicts of interest to disclose. diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (MRI), the pancreatic nodule showed hyperintensity on T2-weighted images, while the hepatic nodule demonstrated hypointensity in the hepatobiliary phase ( Fig. 1C  and D) . Both nodules exhibited high signal intensity on diffusionweighted MRI (Fig. 1E and F) .
Histopathological imaging of the endoscopic ultrasonography (US)-guided fine-needle aspiration biopsy sample from the pancreatic tumor revealed adenocarcinoma with anisonucleosis, nuclear enlargement, and hyperchromasia that were consistent with PDAC ( Fig. 2A) . The pancreatic tumor was immunohistologically positive for cytokeratin (CK) 7 and negative for CK20 ( Fig. 2B and C) . Moreover, US-guided percutaneous biopsy of the hepatic nodule revealed a moderately differentiated adenocarcinoma with ductal formation; the nodule was positive for CK7 and negative for CK20 ( Fig. 2D-F) . Discrimination between PDAC with liver metastasis and synchronous PDAC and ICC was essential for determining the course of treatment (i.e., systemic chemotherapy vs hepatopancreatoduodenectomy). However, such discrimination was not possible using CT/MRI images and histopathological analysis.
Accordingly, we investigated KRAS mutation statuses in both tumors. DNA was extracted from the FFPE biopsy samples of the pancreatic and hepatic tumors using the QIAamp DNA FFPE Tissue Kit (Qiagen, Foster City, CA) following the manufacturer's protocol. The oligonucleotide primers were designed to amplify the sequences of exon 2 and exon 3 of KRAS as follows:
0 , and KRAS exon3AS 5 0 -tgcatggcattagcaaagac-3 0 . Amplification of the KRAS gene was performed using Tks Gflex DNA Polymerase (Takara Bio, Shiga, Japan). Sequencing was performed using the Applied Biosystems 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA). This resulted in the detection of a KRAS G12D mutation in the pancreatic tumor; however, no codon 13, 59, and 61 mutations were detected. On the other hand, a KRAS Q61H mutation was detected in the hepatic tumor, although there were no codon 12, 13, or 59 mutations (Table 1) . We confirmed that the same results were obtained by multiplex PCR assaying at an outsourcing laboratory (BML, Inc., Tokyo, Japan).
Based on these results, the patient was diagnosed with synchronous PDAC and ICC; she consequently underwent hepatopancreatoduodenectomy. Histopathological examination of the pancreatic tumor revealed a moderately differentiated ductal adenocarcinoma with vascular and perineural invasion (Fig. 3A) . The hepatic tumor was diagnosed as a moderately differentiated adenocarcinoma with ductal formation that was consistent with ICC ( Fig. 3B) . Additional KRAS sequencing of the surgical specimen was not performed.
Discussion
ICC normally presents as an adenocarcinoma with ductal formation, and is classified into mass-forming, periductalinfiltrating, and intraductal-growth types. [7] On the other hand, the liver is a common site of metastasis, most frequently from gastrointestinal, pancreatic, lung, and breast cancers; many such metastases present as an adenocarcinoma. Therefore, discriminating between ICC and metastatic liver tumors can often be difficult, especially when the tumor is small and of the massforming type.
Immunostaining using antibodies with high organ specificity often plays an important role in the differential diagnosis of metastatic liver tumors. [8] In particular, immunostaining with CK is helpful for discriminating between hepatocellular carcinoma (HCC) and other types of liver tumors, and for determining the primary tumor site once the diagnosis of adenocarcinoma has been established. Normal and neoplastic hepatocytes express CK8 and 18, and are generally negative for CK7, 19, and 20. On the other hand, normal and neoplastic cholangiocytes express CK7, 8, 18, and 19, and are usually negative for CK20. [8] Noting these CK profiles, Shimonishi et al [9] reported that immunostaining of CK7 and 20 is helpful for differentiating HCC and ICC from metastatic adenocarcinomas in the liver. However, the CK profiles of ICC and PDAC are similar [9] ; hence, immunostaining with CK7 and CK20 is of limited value when discriminating ICC from PDAC liver metastasis.
KRAS mutations are common in colorectal cancer (CRC), PDAC, ICC, and lung cancer. [2] [3] [4] [5] In the case described herein, KRAS mutations were detected in both the pancreatic and hepatic tumors. However, the type of mutation was different in each case; the pancreatic tumor showed G12D whereas the hepatic tumor had Q61H. Several studies have shown that intratumoral heterogeneity of KRAS mutational status and KRAS heterogeneity between primary tumor and metastasis is rare in PDAC. [10, 11] Furthermore, KRAS mutations are detectable in 70% to 93% of PDACs. [11, 12] According to previous studies, the most frequent KRAS mutation in PDAC is G12D (46.5-55.2%), followed by G12V (11.1-37.9%), G12R (3.4-14.8%), G12A (2.3-3.7%), G12C (3.4-3.7%), and G12S (3.7%). [13] [14] [15] On the other hand, it was reported that KRAS mutations are detectable in 11.0% to 31.6% of ICCs, with G12D being the most frequently reported; however only mutations at codons 12 and 13 (exon 2) were investigated in these reports. [4, [16] [17] [18] [19] In this case, the discovery of a Q61H mutation in exon 3 of hepatic tumor DNA ruled out PDAC liver metastasis.
The KRAS mutational analysis assay using FFPE samples is well-established and widely utilized for predicting the response to anti-epidermal growth factor receptor monoclonal antibodies (cetuximab and panitumumab) in CRC. [6, [20] [21] [22] Therefore, KRAS mutational analysis can also be applied to FFPE samples from other organs. In fact, Krasinskas et al [23] reported the utility of KRAS mutational analysis for distinguishing pancreatic meta- static adenocarcinomas from primary lung adenocarcinomas. To our knowledge, this is the first case report of synchronous PDAC and ICC diagnosed by KRAS mutational analysis; our findings suggest that such analyses from FFPE needle biopsy samples may be utilized to differentiate between primary hepatic tumors and metastasis to the liver. This case report was prepared in accordance with the CARE Statement. [24] 
